 | Up a level |
Drilon, Alexander, Siena, Salvatore, Dziadziuszko, Rafal 
ORCID: 0000-0001-8080-9843, Barlesi, Fabrice, Krebs, Matthew G., Shaw, Alice T., de Braud, Filippo, Rolfo, Christian, Ahn, Myung-Ju, Wolf, Juergen, Seto, Takashi, Cho, Byoung Chul, Patel, Manish R., Chiu, Chao-Hua, John, Thomas, Goto, Koichi, Karapetis, Christos S., Arkenau, Hendrick-Tobias, Kim, Sang-We, Ohe, Yuichiro, Li, Yu-Chung, Chae, Young K., Chung, Christine H., Otterson, Gregory A., Murakami, Haruyasu, Lin, Chia-Chi, Tan, Daniel S. W., Prenen, Hans, Riehl, Todd, Chow-Maneval, Edna, Simmons, Brian, Cui, Na, Johnson, Ann, Eng, Susan, Wilson, Timothy R. and Doebele, Robert C.
(2020).
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Lancet Oncol., 21 (2).
S. 261 - 271.
NEW YORK:
ELSEVIER SCIENCE INC.
ISSN 1474-5488
Paz-Ares, Luis, Dziadziuszko, Rafal, Drilon, Alexander, John, Thomas, Krebs, Matthew, Demetri, George, Shaw, Alice T., Siena, Salvatore, Wolf, Juergen, Farago, Anna F., Simmons, Brian, Pitcher, Bethany, Huang, Xinhui and Doebele, Robert (2020). Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors or ROS1-Positive NSCLC with CNS Metastases. Oncol. Res. Treat., 43. S. 235 - 236. BASEL: KARGER. ISSN 2296-5262